We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
News

TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S

TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
News

TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

TINA molecules are intercalators placed at the 5' end of primers to stabilize duplex formation. Their unique properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA may find applications wherever an enhanced Tm is required such as triplex formation or potentially even gene silencing.

"At QuantiBact we strive to make our technologies available throughout the research and diagnostic communities. We appreciate being able to work with dedicated companies that hold high recognition in the market place. The market position as well as in depth knowledge of nucleic acids embedded within TriLink will enable us to further reach our goal," says Palle Schelde, CEO, Managing Director, QuantiBact.

"At TriLink we pride ourselves on our quality and our ability to handle unique nucleic acid modifications. This makes us an ideal manufacturer of TINA oligos," stated Richard Hogrefe, Ph.D., President and CEO of TriLink. "We are excited to work with the great folks at Quantibact and see how this technology might advance molecular diagnostics."

Advertisement